Weight Loss Medications Show Promise in Preventing Obesity-Related Cancers
The drugs were tied to a 41% lower overall risk, with the strongest reduction seen in tirzepatide users, researchers said.
- On Monday, a study published in the Annals of Oncology found GLP-1 receptor agonists are associated with a 41% lower risk of obesity-related cancers in obese, non-diabetic adults.
- Researchers analyzed records from 229,467 obese, non-diabetic patients using the TriNetX database, comparing GLP-1 RAs users against individuals receiving only diet and exercise counseling over a two-year follow-up period.
- Protective effects were even more pronounced in specific subgroups: men experienced a nearly 70% risk reduction, while women saw a 58% decline in endometrial cancer incidence, a malignancy closely linked to obesity.
- Dr. Aparna Kamat, director of the Division of Gynecologic Oncology at Houston Methodist Hospital, said the results "may reach further and transform how we think about cancer prevention."
- Experts caution that these findings do not prove causation and require long-term clinical trials to establish clear anti-cancer benefits before these medications become a standard preventive strategy.
15 Articles
15 Articles
Large Study Links GLP-1s to Lower Risk of Multiple Cancers
(MedPage Today) -- Patients taking GLP-1 receptor agonists for obesity had a 41% lower risk of obesity-related cancers as compared with patients treated with diet or exercise, a large propensity-matched cohort study showed. After 2 years of follow...
A new study published in the scientific journal Annals of Oncology found a 41% lower risk of obesity-related cancers among overweight patients who used GLP-1 analogues, a class of medications known as weight loss canes. The study was the first to evaluate this effect in patients who did not have diabetes, another diagnosis for which drugs are widely used. Know if you are a 'cafeinate': Do our quiz and test your knowledge about coffee What expert…
Weight loss jabs 'should be probed as cancer prevention agents' after US study
Scientists say a new study into weight loss drugs like Mounjaro, Wegovy and Ozempiccan suggest the impact of GLP-1 medicines "may reach further and transform how we think about cancer prevention"
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
